Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The information in our articles is NOT intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice
Monitoring thyroid safety with GLP-1 agonists provides reassurance
Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes
Fill the online form now or email: [email protected] Summary: Key Takeaways The Medications Are Different, But the Risks Are Similar Semaglutide drugs (Ozempic, Wegovy): Single GLP-1 agonist Novo Nordisk manufacturer Longer track record Most lawsuits filed Tirzepatide drugs (Mounjaro, Zepbound): Dual GLP-1/GIP agonist Eli Lilly manufacturer Newer to market Growing litigation All drugs: Slow gastric emptying (the dangerous mechanism) Can cause severe gastroparesis Associated with bowel obstruction, ileus, vision loss Subject to failure-to-warn lawsuits in MDL 3094 Legal Claims Apply Regardless of Which Drug You Took Gastroparesis claims require objective testing (gastric emptying scan) Both diabetes and weight-loss patients can file Multiple drug exposure doesnt disqualify you Bellwether trials coming mid-2026 Statute of limitations: 2-4 years depending on state If Youve Been Injured, Act Now Time is critical: Statutes of limitations are running Evidence must be preserved Proper diagnostic testing required Early filing is advantageous You deserve answers: Free case evaluation No cost unless we win Experienced attorneys Compassionate support Dont wait another day
PlexusDx takes a different approach: combining compounded GLP-1 medications from licensed 503A pharmacies with optional genetic testing to support personalized provider conversations rather than algorithmic matching alone
US$ 23.72
US$ 22.77
US$ 23.47
US$ 24.59
US$ 28.12
US$ 23.79
